The Manufacturers Life Insurance Company Takes Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

The Manufacturers Life Insurance Company bought a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,432 shares of the company’s stock, valued at approximately $145,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. RA Capital Management L.P. boosted its position in shares of Mineralys Therapeutics by 52.6% during the first quarter. RA Capital Management L.P. now owns 4,850,984 shares of the company’s stock valued at $62,626,000 after buying an additional 1,672,508 shares during the last quarter. SR One Capital Management LP boosted its holdings in Mineralys Therapeutics by 12.4% during the 1st quarter. SR One Capital Management LP now owns 2,016,822 shares of the company’s stock worth $26,037,000 after acquiring an additional 222,222 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Mineralys Therapeutics by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 982,932 shares of the company’s stock worth $12,690,000 after acquiring an additional 4,952 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Mineralys Therapeutics by 3.2% in the 2nd quarter. American Century Companies Inc. now owns 743,140 shares of the company’s stock worth $8,695,000 after acquiring an additional 23,170 shares in the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Mineralys Therapeutics in the first quarter valued at about $4,234,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics Price Performance

MLYS stock opened at $14.40 on Friday. The firm has a 50 day simple moving average of $12.12 and a two-hundred day simple moving average of $12.45. The stock has a market cap of $714.95 million, a PE ratio of -6.58 and a beta of 1.93. Mineralys Therapeutics, Inc. has a one year low of $5.85 and a one year high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same period last year, the firm earned ($0.31) earnings per share. On average, research analysts expect that Mineralys Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Thursday, August 15th.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the transaction, the chief financial officer now directly owns 236,854 shares in the company, valued at approximately $3,214,108.78. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Jon Congleton sold 15,271 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the completion of the transaction, the chief executive officer now owns 895,941 shares of the company’s stock, valued at $12,113,122.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.57, for a total value of $145,972.49. Following the completion of the transaction, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at approximately $3,214,108.78. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 576,028 shares of company stock valued at $7,529,936 in the last 90 days. Insiders own 33.24% of the company’s stock.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.